Ser1157

Site Information
KSEVAVLsPEKAEND SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4274350

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , HCT116 (intestinal) ( 4 ) , HeLa (cervical) ( 2 ) , HeLa S3 (cervical) ( 5 ) , HeLa_Meta (cervical) ( 3 ) , HeLa_Pro (cervical) ( 3 ) , HeLa_Telo (cervical) ( 3 )

Upstream Regulation
Treatments:	MG132_withdrawal ( 3 ) , nocodazole ( 5 ) , thymidine ( 5 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81 20097925 Curated Info
4	Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64 19369195 Curated Info
5	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info